30 March 2014

ASX ANNOUNCEMENT

A$2.35 MILLION RAISED UNDER SHARE PURCHASE PLAN

Brisbane, Australia - ImpediMed Limited (ASX:IPD) (“ImpediMed” or the “Company”) is pleased to announce that it has successfully completed its Share Purchase Plan (“SPP”) having raised approximately A$2.35 million.

The SPP which closed on 24 April, will result in the issue of approximately 12.1 million new shares (“New Shares”) at an issue price of A$0.195 per New Share.

Together with the recent institutional placement (“Placement”) which raised A$8.8 million, ImpediMed has successfully raised approximately A$11.15 million (before costs). This new funding positions the Company strongly to accelerate the commercialisation of our L-Dex system in the US lymphoedema market.

The New Shares are expected to be issued on 1 May 2014.

The Company thanks all shareholders who supported the Placement and the SPP.

Steve Denaro – Company Secretary

For further information contact: Richard Carreon, ImpediMed CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

About ImpediMed
ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit www.impedimed.com.au